ABION Valuation

Is A203400 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A203400 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A203400's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A203400's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A203400?

Key metric: As A203400 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A203400. This is calculated by dividing A203400's market cap by their current book value.
What is A203400's PB Ratio?
PB Ratio	13.1x
Book	₩14.92b
Market Cap	₩199.80b

A203400 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	156.6x
Enterprise Value/EBITDA	-6.2x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does A203400's PB Ratio compare to its peers?

The above table shows the PB ratio for A203400 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	3.6x
A083790 CG Invites	1.7x	n/a	₩199.9b
A182400 NKMAX	1.3x	n/a	₩172.7b
A174900 AbClon	9.4x	n/a	₩244.0b
A011000 GeneOne Life Science	2x	n/a	₩171.2b
A203400 ABION	13.1x	n/a	₩199.8b

Price-To-Book vs Peers: A203400 is expensive based on its Price-To-Book Ratio (13.1x) compared to the peer average (3.6x).

Price to Book Ratio vs Industry

How does A203400's PB Ratio compare vs other companies in the KR Biotechs Industry?

3 Companies	Price / Book	Estimated Growth	Market Cap
A377740 BioNote	0.3x	n/a	US$334.25m
A950210 Prestige BioPharma	0.4x	n/a	US$126.23m
A109960 AP Healthcare	0.3x	n/a	US$68.18m

No more companies available in this PB range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: A203400 is expensive based on its Price-To-Book Ratio (13.1x) compared to the KR Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is A203400's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A203400 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	13.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A203400's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩265,000.00

-1.3%

69.8%

Medy-Tox

₩867.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩129,100.00

4.7%

-41.2%

J2KBIO

₩52.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,650.00

1.7%

n/a